(RTTNews) - Monday, Estrella Immunopharma (ESLA), a clinical-stage biopharmaceutical company for treating cancer and autoimmune diseases, appointed Cynthia Pussinen as the Chief Executive Officer and Board Chair, effective October 25, 2026. She succeeds Cheng Liu, who will become
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.